Education
About Us
Working with TipRanks
Follow Us
Caris Life Sciences, Inc. (CAI)
NASDAQ:CAI
CAI Stock Chart & Stats
$28.78
--
Market closed
$28.78
--
Day’s Range― - ―
52-Week Range$22.86 - $42.50
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.21M
Market Cap
$8.01B
Enterprise Value$7.21B
Total Cash (Recent Filing)$755.49M
Total Debt (Recent Filing)$426.74M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding282,146,900
10 Day Avg. Volume1,269,956
30 Day Avg. Volume2,208,415
Financial Highlights & Ratios
PEG Ratio-0.52
Price to Book (P/B)-2.85
Price to Sales (P/S)17.30
P/FCF Ratio-28.11
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue13.88
Enterprise Value/Gross Profit22.65
Enterprise Value/Ebitda-83.58
Forecast
1Y Price Target
$37.60Price Target Upside30.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.23
Revenue Forecast (FY)$984.99M
Bulls Say, Bears Say
Bulls Say
Proprietary Data And AIA large proprietary tumor and matched clinical dataset enables advanced AI models for therapy selection, creating a differentiated product moat and supporting commercial differentiation.
Reimbursement And CoverageHigher reimbursement rates and expanding insurance coverage for molecular tests improve revenue visibility and support meaningful upside as testing adoption grows.
Revenue And Margin ExpansionStrong price realization in the molecular testing business combined with accelerating payer wins is driving notable revenue growth and margin improvement.
Bears Say
Pipeline Development RiskMost pipeline programs remain in early-stage development, creating substantial clinical and commercial execution risk that could delay or limit future product launches.
Regulatory And Commercialization UncertaintyLimited clarity on regulatory pathways and commercialization strategy for new tests increases the risk of timing setbacks and higher launch costs.
Valuation Pressure From UncertaintyUncertainty around the viability and timing of pipeline programs could cap upside potential and keep the stock trading near perceived fair value.
Caris Life Sciences, Inc. News
CAI FAQ
What was Caris Life Sciences, Inc.’s price range in the past 12 months?
Caris Life Sciences, Inc. lowest stock price was $22.86 and its highest was $42.50 in the past 12 months.
What is Caris Life Sciences, Inc.’s market cap?
Caris Life Sciences, Inc.’s market cap is $8.01B.
When is Caris Life Sciences, Inc.’s upcoming earnings report date?
Caris Life Sciences, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 221 days.
How were Caris Life Sciences, Inc.’s earnings last quarter?
Caris Life Sciences, Inc. released its earnings results on Nov 05, 2025. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of -$0.175 by $0.255.
Is Caris Life Sciences, Inc. overvalued?
According to Wall Street analysts Caris Life Sciences, Inc.’s price is currently Undervalued.
Does Caris Life Sciences, Inc. pay dividends?
Caris Life Sciences, Inc. pays a Quarterly dividend of $0.3 which represents an annual dividend yield of N/A. See more information on Caris Life Sciences, Inc. dividends here
What is Caris Life Sciences, Inc.’s EPS estimate?
Caris Life Sciences, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Caris Life Sciences, Inc. have?
Caris Life Sciences, Inc. has 282,146,900 shares outstanding.
What happened to Caris Life Sciences, Inc.’s price movement after its last earnings report?
Caris Life Sciences, Inc. reported an EPS of $0.08 in its last earnings report, beating expectations of -$0.175. Following the earnings report the stock price went down -15.748%.
Which hedge fund is a major shareholder of Caris Life Sciences, Inc.?
Currently, no hedge funds are holding shares in CAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Caris Life Sciences, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.60 (30.65% Upside)
$37.60 (30.65% Upside)
Blogger Sentiment
Neutral
CAI Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 446.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $110.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 13.8%
Last 30 Days ▲ 13.8%
Company Description
Caris Life Sciences, Inc.
Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and machine learning algorithms. The company's molecular profiling services portfolio includes MI Profile, a tissue-based molecular profiling solution; and Caris Assure, a blood-based molecular profiling solution for cancer treatment. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company was founded in 2008 and is headquartered in Irving, Texas.
CAI Company Deck
CAI Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Caris Life Sciences delivered an outstanding quarter with record-breaking revenue growth, improved gross margins, and positive profitability metrics. The company achieved significant milestones including a strong balance sheet and increased ASP. However, challenges remain in pharma revenue and the dependency on revenue true-ups. The complex process for MRD approval also presents a challenge.View all CAI earnings summariesCAI Stock 12 Month Forecast
Average Price Target
$37.60
▲(30.65% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---